J&J says Phase 3 ICONIC-LEAD trial shows ICOTYDE sustains plaque psoriasis clearance through 2 years
Bitget2026/10/09 11:01Johnson & Johnson disclosed new two-year Phase 3 ICONIC-LEAD results for oral psoriasis drug ICOTYDE, already presented at Fall Clinical Dermatology 2026. Study showed durable skin clearance and sustained itch improvement in adults and adolescents through two years of treatment. Patients who stopped therapy and later restarted generally regained strong disease control within months. Safety profile remained consistent over two years, with no new safety concerns flagged. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610090700PR_NEWS_USPR_____NY66113) on October 09, 2026, and is solely responsible for the information contained therein.
- Johnson & Johnson disclosed new two-year Phase 3 ICONIC-LEAD results for oral psoriasis drug ICOTYDE, already presented at Fall Clinical Dermatology 2026.
- Study showed durable skin clearance and sustained itch improvement in adults and adolescents through two years of treatment.
- Patients who stopped therapy and later restarted generally regained strong disease control within months.
- Safety profile remained consistent over two years, with no new safety concerns flagged.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Trader Gu Jingci: November 9 Bitcoin/Ethereum Trading Strategy and Market Analysis
United States Dollar Index remains subdued as lower oil prices ease inflation pressure
Crypto prices
More
